Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction

被引:161
|
作者
Ungar, Leo [1 ]
Altmann, Andre [1 ]
Greicius, Michael D. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Funct Imaging Neuropsychiat Disorders FIND Lab, Stanford, CA 94305 USA
关键词
Alzheimer's disease; APOE: Gender; Genetics; Aging and aging-related diseases; Neuroimaging; EPSILON; 4; ALLELE; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; RESTING-STATE FMRI; E TYPE-4 ALLELE; APOE GENOTYPE; GENETIC RISK; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; HIPPOCAMPAL VOLUMES;
D O I
10.1007/s11682-013-9272-x
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Alzheimer's disease (AD) is an increasingly prevalent, fatal neurodegenerative disease that has proven resistant, thus far, to all attempts to prevent it, forestall it, or slow its progression. The epsilon 4 allele of the Apolipoprotein E gene (APOE4) is a potent genetic risk factor for sporadic and late-onset familial AD. While the link between APOE4 and AD is strong, many expected effects, like increasing the risk of conversion from MCI to AD, have not been widely replicable. One critical, and commonly overlooked, feature of the APOE4 link to AD is that several lines of evidence suggest it is far more pronounced in women than in men. Here we review previous literature on the APOE4 by gender interaction with a particular focus on imaging-related studies.
引用
收藏
页码:262 / 273
页数:12
相关论文
共 50 条
  • [1] Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction
    Leo Ungar
    Andre Altmann
    Michael D. Greicius
    Brain Imaging and Behavior, 2014, 8 : 262 - 273
  • [2] Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease
    Bretsky, PM
    Buckwalter, JG
    Seeman, TE
    Miller, CA
    Poirier, J
    Schellenberg, GD
    Finch, CE
    Henderson, VW
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1999, 13 (04): : 216 - 221
  • [3] Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?
    Lo Vecchio, Filomena
    Bisceglia, Paola
    Imbimbo, Bruno Pietro
    Lozupone, Madia
    Latino, Raffaela Rita
    Resta, Emanuela
    Leone, Maurizio
    Solfrizzi, Vincenzo
    Greco, Antonio
    Daniele, Antonio
    Watling, Mark
    Panza, Francesco
    Seripa, Davide
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [4] Apolipoprotein E and Alzheimer's disease
    Benjamin R.Troutwine
    Laylan Hamid
    Colton R.Lysaker
    Taylor A.Strope
    Heather M.Wilkins
    Acta Pharmaceutica Sinica B, 2022, 12 (02) : 496 - 510
  • [5] Apolipoprotein E and Alzheimer's disease
    Strittmatter, WJ
    Roses, AD
    ANNUAL REVIEW OF NEUROSCIENCE, 1996, 19 : 53 - 77
  • [6] Apolipoprotein E and Alzheimer's disease
    Troutwine, Benjamin R.
    Hamid, Laylan
    Lysaker, Colton R.
    Strope, Taylor A.
    Wilkins, Heather M.
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (02) : 496 - 510
  • [7] Apolipoprotein E and Alzheimer's disease
    Strittmatter, WJ
    ALZEHEIMER'S DISEASE: A COMPENDIUM OF CURRENT THEORIES, 2000, 924 : 91 - 92
  • [8] Apolipoprotein E and Alzheimer's disease
    Stephens, D
    JOURNAL OF THE ROYAL SOCIETY OF HEALTH, 1996, 116 (01): : 41 - 43
  • [9] Risk of Alzheimer's disease is associated with an interaction of apolipoprotein E and paternal age
    Farrer, LA
    Cupples, LA
    Foley, E
    Auerbach, S
    Wolf, P
    DAgostino, R
    Ordovas, J
    Schaefer, E
    Growdon, J
    Haines, J
    Volicer, L
    Wells, J
    Kurz, A
    Green, R
    Chui, H
    Duara, R
    NEUROLOGY, 1996, 46 (02) : 6023 - 6023
  • [10] Estrogen and Alzheimer's disease risk: Absence of interaction with apolipoprotein E genotype
    Henderson, VW
    Green, RC
    Cupples, LA
    Benke, K
    Farrer, LA
    NEUROLOGY, 2002, 58 (07) : A106 - A106